Viracor-IBT Laboratories
 | This article contains promotional content. (April 2020) |
Viracor Eurofins Laboratories is a diagnostic laboratory specializing in infectious disease, immunology and allergy testing for immunocompromised and critical patients. Viracor Eurofins works with medical professionals, transplant teams, reference labs and bio-pharmaceutical companies.
Viracor-IBT has CLIA clinical laboratory certification as both an Infectious Disease Laboratory and as an Allergy & Immunology Laboratory.[1]
History
[edit]Viracor-IBT was created through the merger of two specialty diagnostic testing labs, Viracor Laboratories and IBT Laboratories.[2] Founded by Dr. Konstance Knox and Dr. Donald Carrigan in Milwaukee County in 2000, Viracor was among the first to commercially offer real-time quantitative PCR assays to diagnose patients with Adenovirus, BK virus and JC virus, among others. Founded in 1983, IBT was the first laboratory to offer a test to definitively diagnose autoimmune causes of chronic hives and developed the first commercially available test to measure pneumococcal antibodies.
On 1 July 2014, Ampersand Capital Partners completed the sale of Viracor-IBT Laboratories to Eurofins Scientific for $255 million. The company continued to be known as Viracor-IBT.[3]
Expertise
[edit]The core areas of expertise for Viracor-IBT are:[4]
- Custom Assay Development
- Infectious Disease Testing
- Immune Monitoring
- Biomarkers & Bioanalyitics
References
[edit]- ^ "Licenses & Certifications". Viracor-IBT Laboratories, Inc. Retrieved 8 November 2017.
- ^ "ViraCor, IBT Laboratories merge". Kansas City Business Journal. 30 June 2009. Retrieved 8 November 2017.
- ^ Ampersand Capital Partners. "Ampersand Sells Viracor-IBT To Eurofins For $255 Million". PR Newswire. Retrieved 8 November 2017.
- ^ "Areas of Expertise". Viracor-IBT Laboratories, Inc. Retrieved 8 November 2017.